Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Recommendations were announced by the US Public Health Service on 4 March 1983, when their principles were endorsed by the American Red Cross, the American Association of Blood Banks, and the Council of Community Blood Centers.

  • Read more about Recommendations were announced by the US Public Health Service on 4 March 1983, when their principles were endorsed by the American Red Cross, the American Association of Blood Banks, and the Council of Community Blood Centers.

In the 1997 Krever Report Mr Justice Krever summarised the Centers for Disease Control (CDC) meeting of January 1983 by noting "there was no consensus on the question whether AIDS was caused by a transmissible agent, on the risk of AIDS from blood donations, or on the desirability of introducing new methods of donor screening or testing to reduce the risk of transmission."

  • Read more about In the 1997 Krever Report Mr Justice Krever summarised the Centers for Disease Control (CDC) meeting of January 1983 by noting "there was no consensus on the question whether AIDS was caused by a transmissible agent, on the risk of AIDS from blood donations, or on the desirability of introducing new methods of donor screening or testing to reduce the risk of transmission."

During a Centers for Disease Control (CDC) meeting, Dr Francis slammed his fist on the table and asked in effect how many AIDS cases, or how many deaths, would be needed before those attending took action.

  • Read more about During a Centers for Disease Control (CDC) meeting, Dr Francis slammed his fist on the table and asked in effect how many AIDS cases, or how many deaths, would be needed before those attending took action.

The California Morbidity and Mortality Weekly Report confirmed that the three people with haemophilia whose cases had been reported in July 1982 had all died

  • Read more about The California Morbidity and Mortality Weekly Report confirmed that the three people with haemophilia whose cases had been reported in July 1982 had all died

Individual clinicians, gay rights groups, and the National Hemophilia Foundation all joined calls at various stages to obtain more information before taking steps or "stigmatising" donors or users of blood products.

  • Read more about Individual clinicians, gay rights groups, and the National Hemophilia Foundation all joined calls at various stages to obtain more information before taking steps or "stigmatising" donors or users of blood products.

Dr Steven Ojala of Cutter wrote after one meeting in January 1983, quoting a colleague from Hyland, that 'it is unusual for us [the commercial companies] to come away wearing the white hats while the "volunteer" sector wears the black'

  • Read more about Dr Steven Ojala of Cutter wrote after one meeting in January 1983, quoting a colleague from Hyland, that 'it is unusual for us [the commercial companies] to come away wearing the white hats while the "volunteer" sector wears the black'

The National Hemophilia Foundation broke the news to its members that the CDC believed that the immune deficiency might be caused by a virus transmitted through blood or blood products as was hepatitis, but advised that the risk of contracting this immunosuppressive agent was minimal.

  • Read more about The National Hemophilia Foundation broke the news to its members that the CDC believed that the immune deficiency might be caused by a virus transmitted through blood or blood products as was hepatitis, but advised that the risk of contracting this immunosuppressive agent was minimal.

The FDA wrote to manufacturers of plasma products to tell them that "although the cause of this outbreak is unknown, the information suggests that a transmissible agent might be involved and concern about transmission through blood and blood products has been raised."

  • Read more about The FDA wrote to manufacturers of plasma products to tell them that "although the cause of this outbreak is unknown, the information suggests that a transmissible agent might be involved and concern about transmission through blood and blood products has been raised."

CDC Epidemiological Notes and Reports Update on Kaposi's Sarcoma and Opportunistic Infections in Previously Health Persons documented that of the 355 cases reported then, 16% were heterosexual - and a quarter of these were women. Only about half were intravenous drug users.

  • Read more about CDC Epidemiological Notes and Reports Update on Kaposi's Sarcoma and Opportunistic Infections in Previously Health Persons documented that of the 355 cases reported then, 16% were heterosexual - and a quarter of these were women. Only about half were intravenous drug users.

The Sub-Committee on Biological Products stated that on grounds of safety, quality and efficacy it was unable to recommend that the Product Licence be varied for Travenol Laboratories Ltd Hemofil product. It considered that justification should be provided for the inclusion and choice of the heat treatment step and that there was inadequate evidence as to the safety and efficacy of the product.

  • Read more about The Sub-Committee on Biological Products stated that on grounds of safety, quality and efficacy it was unable to recommend that the Product Licence be varied for Travenol Laboratories Ltd Hemofil product. It considered that justification should be provided for the inclusion and choice of the heat treatment step and that there was inadequate evidence as to the safety and efficacy of the product.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 296
  • Page 297
  • Page 298
  • Page 299
  • Current page 300
  • Page 301
  • Page 302
  • Page 303
  • Page 304
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.